Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma, Inc. (LYEL)
:LYEL
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.65 - $32.40
Previous CloseN/A
Volume124.06K
Average Volume (3M)62.30K
Market Cap
$163.54M
Enterprise Value-$85.33M
Total Cash (Recent Filing)$301.18M
Total Debt (Recent Filing)$48.85M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Nov 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,457,450
10 Day Avg. Volume63,624
30 Day Avg. Volume62,295
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.52
Enterprise Value/Revenue-1.31K
Enterprise Value/Gross Profit-1.31K
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$11.00Price Target Upside3.97% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyLYL314 data achieves impressive efficacy metrics, with early signs of durability.
Financial StabilityLyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.
Regulatory DesignationRMAT designation for LYL314 is a positive sign in turbulent times at the FDA.
Bears Say
Competition And Market SaturationThe CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.
Development RisksThe bar is quite high for LYL314 and its efficacy differentiation has narrowed since the impressive single-center trial; thus, there is an added layer of risk for a development-stage CAR-T aiming to displace SOC with a high bar to overcome.
Financial PerformanceLyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma, Inc.’s price range in the past 12 months?
Lyell Immunopharma, Inc. lowest stock price was $7.65 and its highest was $32.40 in the past 12 months.
What is Lyell Immunopharma, Inc.’s market cap?
Lyell Immunopharma, Inc.’s market cap is $163.54M.
When is Lyell Immunopharma, Inc.’s upcoming earnings report date?
Lyell Immunopharma, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 91 days.
How were Lyell Immunopharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Lyell Immunopharma, Inc. overvalued?
According to Wall Street analysts Lyell Immunopharma, Inc.’s price is currently Undervalued.
Does Lyell Immunopharma, Inc. pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
What is Lyell Immunopharma, Inc.’s EPS estimate?
Lyell Immunopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyell Immunopharma, Inc. have?
Lyell Immunopharma, Inc. has 15,457,450 shares outstanding.
What happened to Lyell Immunopharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lyell Immunopharma, Inc.?
Currently, no hedge funds are holding shares in LYEL
Lyell Immunopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.00 (3.97% Upside)
$11.00 (3.97% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 473.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.42%
12-Months-Change
Fundamentals
Return on Equity
-71.20%
Trailing 12-Months
Asset Growth
-38.09%
Trailing 12-Months
Company Description
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$11.00
▲(3.97% Upside)
Technical Analysis
Ownership Overview
15.94% Insiders
7.07% Mutual Funds
19.78% Other Institutional Investors
50.74% Public Companies and
Individual Investors